Lilly Acquires Adverum for One-Time Eye Disease Gene Therapy
Eli Lilly announces acquisition of Adverum Biotechnologies for up to $12.47 per share to advance Ixo-vec, a promising one-time gene therapy for age-related macular degeneration.
/ 1 item
#ADVM↓